ImmunityBio told investors it was sitting on a breakthrough. A cancer treatment with massive potential. Even framed as a path toward a cure.

But that promise did not match reality.

In January 2026, the company’s top executive went on a podcast claiming its drug Anktiva could treat all cancers and even prevent cancer. Big statements. Game changing. But behind the scenes, regulators saw something very different.

By March 2026, the FDA issued a warning letter saying those claims were false and misleading. The drug was only approved for a narrow type of bladder cancer. Not all cancers. Not prevention. Not a cure.

When the warning letter became public, the stock dropped about 21%.

Investors were stunned. Confidence cracked. The story unraveled fast.

Now, more investors are joining the lawsuit.

Super Micro told investors it was riding the AI wave. Record demand. Explosive growth. Billions in revenue.

But behind the scenes, a very different story was unfolding.

Starting in April 2024, the company reported massive sales driven by AI servers and global demand. Executives pointed to strong growth across the U.S. and Asia and kept raising expectations. Through 2025, they doubled down. Bigger numbers. Bigger forecasts. Everything looked unstoppable.

But according to the complaint, a key piece was missing. A significant chunk of those sales allegedly involved servers diverted to China in violation of U.S. export laws. Internal controls were weak. Compliance wasn’t what investors were led to believe.

Then in March 2026, the allegations became public. An indictment was unsealed alleging a scheme involving roughly $2.5 billion in server sales.

The stock dropped about 33% in a single day. Investors were stunned.

Now, more investors are joining the lawsuit.

Atara told investors it was on the verge of a breakthrough. A first of its kind cancer therapy. Strong data. FDA approval in sight.

But behind the scenes, serious problems were building.

In May 2024, Atara submitted its FDA application, claiming promising trial results and a smooth path forward. By July, the FDA granted priority review. Executives kept saying the application was on track for approval.

Then January 2025 hit. The FDA rejected the application, pointing to manufacturing issues. The stock dropped about 40% in a single day. Days later, regulators placed a clinical hold, pausing new trial enrollment.

Atara maintained the issues could be addressed and resubmitted. But in January 2026, the FDA rejected it again, this time saying the trial itself was flawed. The stock collapsed nearly 57%.

Investors were stunned.

Now, more investors are joining the lawsuit.

Lufax told investors its financials were strong. Controls were effective. Profits were accurate.

But behind the scenes, the financials were misstated.

In April 2023 and again in April 2024, Lufax filed annual reports claiming solid internal controls and accurate financials. Executives signed off. Everything looked clean. But the complaint says controls were deficient and financial results were misstated.

Then in January 2025, the story cracked. The company’s auditor raised serious concerns about certain transactions and said prior audit opinions could no longer be relied upon.

The stock dropped about 14% in a day and kept sliding.

By February 2026, Lufax admitted it had to restate results. Net profit fell by hundreds of millions.

Investors were stunned. Confidence collapsed.

Now, more investors are joining the lawsuit.

Power Solutions told investors it was tapping into booming data center demand. High growth. Higher margins. A booming future.

But behind the scenes, that story was starting to crack.

In May 2025, the company reported record results and strong demand from data centers. By August, executives doubled down, pointing to strong demand and growth tied to data centers.

Then November hit. Margins dropped to about 24%, blamed on “temporary inefficiencies.” Growth expectations pointed to a sharp deceleration. The stock fell about 19% in a day.

And it got worse. In March 2026, the company admitted margins had dropped again, down about 8% year over year, tied to ongoing production problems. The stock plunged nearly 30%.

Investors were left stunned. A lawsuit alleges the company overstated demand in the data center market and downplayed the cost and impact of production inefficiencies.

Now, more investors are joining the lawsuit.

Concorde told investors it offered technology-driven security services with recurring revenue.

But according to a recently filed complaint, a coordinated promotion scheme was driving the stock.

In April 2025, Concorde went public at $4 a share, highlighting recurring revenue and technology-based services. By June, executives were still touting growth and new contracts.

But according to the complaint, the surge was driven by a coordinated promotion scheme—not fundamentals. Online posts, chat groups, even impersonators posing as financial advisors promoted the stock with misleading claims.

The price surged to over $30 by early July. Then on July 10, it all collapsed. The stock crashed about 80% in a single day.

Investors were stunned. Confidence vanished.

A lawsuit now alleges investors were misled.

Gemini sold investors a bold vision. A global crypto platform. Expanding users. Expanding markets. Real growth.

But key risks weren’t disclosed.

In September 2025, Gemini went public, raising nearly $400 million and highlighting plans to grow its core exchange and expand internationally. By November, executives were still emphasizing global expansion and user growth. Then in December, they introduced a new initiative: prediction markets.

And in February 2026, everything flipped.

Gemini announced a major shift in its business. It slashed about 25% of its workforce. It exited major international markets. Then several top executives departed.

Investors were blindsided. The stock fell sharply. Confidence collapsed.

Now, more investors are joining the lawsuit.

Alight told investors a new era had arrived. A seasoned CEO. Strong growth. Reliable dividends. A steady path forward.

But behind the scenes, that story was already breaking down.

In November 2024, Alight promised improving margins, growing pipeline and improving bookings trends, and a consistent return of capital. By February 2025, they doubled down with confident guidance and long term growth targets.

Then August 2025 hit. The company reported weak results, cut guidance, and revealed slower bookings, weaker project revenue, and execution issues. The stock dropped about 18% in a single day.

Still, executives maintained confidence in execution and future targets.

Until February 2026. New leadership revealed missed targets, weak bookings, rising costs, and scrapped the dividend entirely. The stock plunged about 38% overnight.

Investors were left stunned. Confidence collapsed.

Now, investors are taking action.

Gartner told investors growth was accelerating. Projected accelerating contract value growth. Pointing to a path toward double-digit growth.

But that story started to crack.

In February 2025, executives promised contract value growth would climb toward 12 to 16% in a normal environment. By May, they maintained that outlook, even as macro conditions became more challenging.

Then August hit. Contract value growth slipped to about 5%. The stock dropped roughly 27% in a single day. But the slowdown continued.

In February 2026, Gartner revealed even weaker growth and a shortfall in its consulting business. Shares fell another 20%.

Investors reacted sharply.

Now, investors are taking action.

Oddity Tech told investors its AI-driven beauty platform was delivering strong growth and profitability.

But behind the scenes, something was going very wrong.

In February 2025, the company celebrated strong revenue growth and said its direct to consumer strategy was thriving. Through April, August, and November 2025, executives kept raising guidance and promising continued momentum.

What investors allegedly didn’t know was that an algorithm change by Oddity’s largest advertising partner was diverting ads into lower-quality auctions. Oddity’s ads were diverted into lower-quality auctions, driving customer acquisition costs sharply higher.

Then on February 25, 2026, the truth came out. Oddity disclosed the disruption and warned first-quarter 2026 revenue could fall about 30% year over year.

Investors panicked. The stock collapsed about 49% in a single day.

Now, a securities class action alleges investors were misled.

Trip.com told investors it was the go to platform for global travel. A powerful one stop shop connecting millions of travelers. The future looked bright.

But behind the scenes, a serious threat was building.

In April 2024, Trip.com told investors antitrust enforcement in China could affect its business. A year later, Trip.com repeated the same warning in its next annual report. Antitrust problems were framed as just a possibility.

According to the complaint, that warning missed the real story. But investors now allege Trip.com had already been facing increasing antitrust scrutiny in China.

Then in January 2026, the truth surfaced. China launched an antitrust investigation accusing Trip.com of abusing its market power.

The stock dropped about 17% in a single day. Confidence disappeared.

Now investors are suing over the alleged misleading statements.

Camping World told investors its data-driven inventory strategy was strengthening margins and positioning the company for growth. Smart inventory. Data driven decisions. A stronger balance sheet than ever.

But the story behind the numbers was very different.

On April 29, 2025, the company reassured investors it could precisely manage inventory and keep margins strong. Executives pointed to strong retail momentum, improving performance across the business and said their systems and data analytics would help keep inventory aligned with market demand.

The lawsuit says that confidence was badly misplaced.

Behind the scenes, demand was weaker than investors were led to believe, and Camping World’s systems could not manage inventory the way executives claimed. Inventory pressures began to emerge. Falling prices. And shrinking margins.

Then the cracks started showing.

On October 28, 2025, the company revealed declining prices and weaker margins. The stock dropped about 25%.

Then on February 24, 2026, even worse news arrived. Losses widened, inventory problems forced corrective actions, and the dividend was paused.

Shareholders watched the stock fall again.

Now, investors have filed a securities class action lawsuit.

monday.com told investors the future looked huge. AI innovation. Enterprise expansion. A bold goal of $1.8 billion in revenue by 2027.

But a recently filed securities lawsuit alleges the story behind the scenes looked very different.

In September 2025, executives confidently laid out that massive revenue target at their Investor Day, saying AI adoption and new products would fuel rapid growth.

Then in November 2025, the company reported solid quarterly revenue but quietly issued softer guidance as sales cycles stretched and momentum slowed. Still, leadership kept repeating the same promise. $1.8 billion by 2027.

Then came February 2026. The company suddenly backed away from that long term target and warned of slower growth ahead.

Investors were stunned. The stock dropped about 21% in a single day.

Now, investors say they were misled. And more shareholders are joining the lawsuit.

Driven Brands told investors its financial reporting was solid. The numbers looked clean. The business looked stable.

But according to a newly filed lawsuit, the company’s financial statements were riddled with accounting errors that went back years.

Starting in May 2023, the company kept filing financial reports that painted a clean picture. Through 2024 and into 2025, executives continued reporting positive financial results and assuring investors that internal controls were effective.

But on February 25, 2026, everything cracked. Driven Brands admitted its financial statements going back to 2023 could not be trusted and needed a sweeping restatement.

The company disclosed errors tied to cash, revenue, expenses, leases, taxes, and even improperly recognized revenue in part of the business. It also revealed material weaknesses in internal controls.

Investors were stunned. The stock fell from about $16.60 to about $10 in a day. Confidence collapsed.

Now investors have filed a securities fraud lawsuit.

Soleno promised a breakthrough. A first of its kind treatment for a rare disorder. Executives said their drug VYKAT XR was safe, effective, and ready to change lives.

But investors later heard a very different story.

In March 2025, Soleno celebrated FDA approval of its drug for Prader Willi syndrome. Executives said the clinical data was strong and the launch was off to a great start.

Then in August 2025, a massive investigative report raised concerns about the company’s clinical trials and potential safety risks. According to the report, some clinical investigators said they had concerns about the drug and were hesitant to prescribe it. Soon after, reports of adverse events began piling up and the launch started to unravel.

By November 2025, Soleno admitted the controversy had disrupted the drug’s rollout and patient use was dropping.

The stock plunged about 27% in a single day.

Investors have now filed a securities fraud class action lawsuit.

For years, Apollo Global told investors the same thing. The firm said it had never done business with Jeffrey Epstein.

But newly released records in 2026 suggested a different story.

Back in 2021, Apollo told investors the firm had never done business with Jeffrey Epstein. Those statements appeared in filings and public disclosures. Investors were told the company had conducted an internal investigation and stood by those conclusions.

But new documents started surfacing in early 2026. Emails and records showed Epstein had communicated with senior Apollo leaders in the 2010s. He discussed tax strategies, received internal financial calculations, and even helped arrange meetings tied to company business. In a recently filed lawsuit, investors allege that was never disclosed. When the news broke in February 2026, confidence cracked.

Apollo’s stock slid and investors were stunned.

Now, investors have filed a securities class action lawsuit.

Franklin BSP Realty Trust told investors the dividend was solid. $0.355 cents a quarter. Presented as sustainable. Supported by confidence in future coverage.

But behind the scenes, the math was not adding up.

On November 5, 2024, executives admitted earnings were not covering the dividend. Still, they said they were “confident” in its long term power.

On February 14, 2025, they repeated it. The payout was appropriate. Confidence in earnings power. By July and October 2025, management again pointed to a “clear path” to support that same dividend.

Then February 11, 2026 hit. After the market closed, the company reported fourth quarter results showing net income and earnings per share down from the prior year — and announced the dividend would be reset to $0.20 per share. The next day, the stock fell about 14% in a single day, closing at $8.71.

Investors were stunned.

Now, shareholders are joining a class action lawsuit to recover their losses.

Snowflake Inc. told investors the growth story was still intact. Consumption was stabilizing. $10 billion in product revenue by 2029 was still the goal.

But behind the scenes, cracks were forming.

On June 27, 2023, executives assured investors usage was “back where we’d expect it to be.” Through August and November, they repeated that consumption was strong and new products would drive growth.

What they didn’t highlight? Product efficiency gains, tiered storage pricing, and new Iceberg tables were expected to create revenue headwinds — reducing storage growth and pressuring consumption.

Then came February 28, 2024. Snowflake lowered its fiscal 2025 outlook, withdrew its external $10 billion product revenue target for 2029, and warned of mounting revenue headwinds. The next day, the stock plunged about 18%, wiping out billions in value.

Investors were stunned. Confidence cracked.

Now, more shareholders are joining the lawsuit.

Navan, Inc. promised investors rapid growth. 33% percent revenue growth. 32% booking growth. A platform built for customers of all sizes across industries.

Then came the IPO in October 2025. Shares priced at $25. Nearly $920 million raised. Confidence was high.

But behind the scenes, something wasn’t in the spotlight.

On October 31, the same day the IPO became effective, Navan had already ramped up sales and marketing spending by 39% in a single quarter. Revenue growth was slowing. The lawsuit alleges sustaining that growth required significantly higher sales and marketing spending.

Investors didn’t learn the full picture until December 15, when Navan reported the spike in spending and announced its CFO was stepping down. The stock dropped about 12% overnight. It later fell as low as about $9.20 per share. Nearly 63% below the IPO price.

Now, investors are fighting back. And more are joining the lawsuit.

Lakeland Industries told investors its acquisition strategy was small, strategic, and quick. Pacific Helmets. Jolly Boots. Global expansion. Strong guidance. Big expectations.

But behind the scenes, those shiny new acquisitions were struggling.

On September 4, 2024, Lakeland missed revenue. Executives blamed shipment delays at Jolly. The stock slipped.

In April 2025, things got worse. Earnings cratered. A major boot order was pushed out. Pacific Helmets was dealing with production problems. The company still insisted its outlook was solid. Then on June 9, 2025, another miss. Tariff delays. Freight costs. More excuses. Finally, on December 9, 2025, the bottom fell out. Revenue missed by about $9 million. Guidance was pulled. The CFO departed.

The stock collapsed nearly 40% in a single day.

Investors were left stunned.

Now, more shareholders are joining the lawsuit.

Zynex told investors it was changing pain management.

Record orders. Record revenue. The Company touted profitability and record results.

But behind the scenes, something else was growing.

Starting in 2021, executives blamed “strong order flow” and sales productivity for soaring numbers. They said doctors needed their non opioid devices. They said demand was real. According to the complaint, it wasn’t.

Prosecutors later alleged Zynex shipped massive amounts of electrodes and supplies patients did not need and sometimes never ordered. Insurers were billed hundreds of millions of dollars. Tricare, a major customer, flagged concerns as early as 2022.

In March 2025, payments were suspended. The stock crashed more than 50% in a single day. By December, Zynex filed for bankruptcy. Weeks later, top executives were indicted.

Investors were left stunned.

Now, more shareholders are joining the lawsuit.

NuScale told investors its small modular reactors were the future of clean energy.

A game changer. A faster, safer path to nuclear power. And they had the perfect partner to make it happen.

Starting in May 2025, NuScale pointed to ENTRA1 as its exclusive global commercialization partner. Executives called it a one stop shop. A seasoned energy platform. A team with decades of experience building and financing major power projects.

In September 2025, ENTRA1 announced a massive deal with the Tennessee Valley Authority. Up to six gigawatts of nuclear power. NuScale celebrated. The stock traded above $57 a share during the Class Period.

Then November hit.

NuScale revealed it had paid ENTRA1 about $495 million in milestone payments tied to that deal. Quarterly losses exploded to more than $530 million. Analysts started asking a simple question. Had ENTRA1 ever actually built or operated anything?

Reports said no. Just three employees. No track record in nuclear. The stock plunged more than 70% from its high.

Now, investors are joining the lawsuit.

Enphase told investors it could control its destiny.

New products. Inventory discipline. Optimistic commentary about demand despite tax credit changes.

It sounded steady. Strategic. Safe.

On April 22,2025, Enphase emphasized discipline in managing channel inventory and introducing new products. In July, after Congress moved up the expiration of the 25D solar tax credit, executives painted an optimistic picture that demand would hold up. In August, Enphase announced new safe harbor agreements and said the channel was in “very good shape.”

The lawsuit alleges that behind the scenes channel inventory was higher than investors were led to believe. And millions in so called safe harbor revenue were pulled forward from the fourth quarter to the third.

Then on October 28, 2025, the truth landed. Revenue guidance was slashed. Shipments were being cut to clear excess inventory. Management warned of a sharp drop ahead.

The stock fell about 15% in a single day. Investors were stunned. Now, more shareholders are joining the lawsuit.

Ostin Technology told investors it was building a high growth display business. A Nasdaq listed company. New capital. Big opportunity.

According to a criminal indictment, prosecutors say it was something else entirely. A carefully orchestrated pump and dump.

In April 2025, Ostin closed a $5 million stock offering at a steep discount. Weeks later, insiders exchanged warrants for more than 70 million shares at zero cost. Then starting in May, social media promotions and WhatsApp groups pushed the stock hard. The price exploded from $0.78 in mid April to $9.40 by June 26. That is a surge of more than 1,000%.

Then came the dump.

On June 26, the stock collapsed 94% in a single day. Nearly $950 million in market value vanished.

Now, stunned investors are fighting back. More shareholders are joining the lawsuit.

PayPal Holdings, Inc. told investors it was about to win checkout.

Big growth. High single digits. Even double digit earnings expansion by 2027.

Executives said their branded checkout revamp was working. New products. Better conversion. Strong U.S. momentum.

But here is what investors did not hear.

On February 25, 2025, leadership laid out bold targets and promised acceleration. On April 29, 2025, they doubled down, pointing to early traction and rising engagement.

Then, on February 3, 2026, everything changed.

PayPal reported disappointing fourth quarter results. Branded checkout was slowing. The company scrapped its 2027 targets. It blamed operational and deployment issues. The CEO was suddenly out. The stock plunged about 20% in a single day.

Investors were stunned. Confidence collapsed.

Now, more investors are joining the lawsuit.

Regenxbio told investors it was on the brink of a breakthrough.

A one time gene therapy. Encouraging biomarker data. No serious safety issues.

It sounded like hope for families and a huge opportunity for shareholders.

Starting in February 2022, the company highlighted positive early results for RGX-111, calling it well tolerated with no drug related serious adverse events. In February2023, executives doubled down, pointing to strong biomarker activity and developmental progress. Even in January 2025, they described the treatment as very promising in a new partnership announcement.

But on January 28, 2026, everything changed.

The FDA slammed RGX-111 with a clinical hold after a brain tumor was identified in a child trial participant, with causality still under review. The stock fell about 18% in a single day.

Investors were stunned. Confidence shaken.

Now, more shareholders are joining the lawsuit.

uniQure told investors it was on the brink of something historic.

A gene therapy that could actually slow Huntington’s disease. FDA aligned. Data locked in. Approval on track for early 2026.

Then everything unraveled.

On September 24, 2025, uniQure announced its AMT-130 trial hit its main goal. They claimed a 75% slowing of disease progression. The stock exploded nearly 250% in a single day. By late October, shares were trading above $70. The company even raised about $345 million dollars to prepare for launch.

But on November 3, 2025, the FDA dropped a bombshell. It no longer agreed that the trial data was adequate primary evidence to support approval. The timeline? Suddenly unclear.

The stock collapsed about 49% in one day.

Now, investors are joining the lawsuit.

Kyndryl told investors its financial controls were solid. Effective. Remediated. Nothing to worry about.

But behind the scenes, the numbers were not adding up.

Starting in August 2024, Kyndryl filed quarterly reports admitting to limited IT control issues, while assuring investors there were no material misstatements. In May 2025, the company went even further. It declared its internal controls fully effective in its annual report.

That reassurance did not last.

On February 9, 2026, Kyndryl stunned the market. It announced it could not file its quarterly report on time. The company revealed an SEC investigation into its financial reporting and admitted there were material weaknesses in its internal controls stretching back to fiscal year 2025. Its prior internal control opinion could no longer be relied upon.

Investors panicked. The stock plunged about 55% in a single day.

Now, more investors are joining the lawsuit.

Inovio told investors it was on the verge of history. A breakthrough DNA medicine. Accelerated FDA approval. A fast track to becoming a full commercial company. It sounded like a turning point.

Starting in October 2023, Inovio said the FDA agreed its Phase I/II data could support accelerated approval for INO-3107. In January 2024, executives promised a BLA filing by the second half of 2024. While promoting that regulatory path, the company raised capital through multiple stock offerings.

But in August 2024, the story cracked. Inovio admitted a manufacturing defect in its CELLECTRA device would delay the filing by about a year. The stock slipped.

Then in December 2025, the real blow landed. The FDA accepted the BLA but designated the review as standard, saying they had not submitted adequate information to justify eligibility for the accelerated approval pathway. Shares plunged about 24% in a single day.

Investors were stunned. Now, more shareholders are joining the lawsuit.

Paysafe told investors it had strong banking relationships. Nearly 100 hundred banks. Solid growth. Clear guidance for 2025. But behind the scenes, the story was very different.

On March 4, 2025, Paysafe issued upbeat guidance, projecting organic growth up to 8%. In May and again in August, executives reaffirmed that outlook, pointing to steady performance in its Merchant Solutions segment.

What investors did not know? The company’s e-commerce business was heavily exposed to a single high-risk client. Credit loss reserves were understated. And some of its higher-risk merchant categories were getting harder to bank.

Then on November 13, 2025, the truth hit. Paysafe reported revenue of about $434 million dollars, missed estimates, posted an $88 million dollar net loss, and slashed full year guidance. The stock plunged 27% in a single day.

Investors were shocked. Confidence collapsed. Now, more investors are joining the lawsuit.

BlackRock TCP sold itself as steady. Disciplined. A safe income play built on carefully valued loans. But behind the scenes, that stability was cracking.

In November 2024, the company told investors its portfolio was improving and its net asset value sat just over $10 a share. Executives said the portfolio had “shown signs of improvement,” highlighting fewer non-accruals and assuring investors they were “working diligently” to resolve credit issues while emphasizing a disciplined, quarterly valuation process.

Then came February 2025. BlackRock TCP admitted its loan portfolio had weakened badly. Non-accrual loans had more than doubled. Losses exploded. Net asset value plunged more than 20% in a year. The stock dropped about 10% in a single day. Still, investors were told things were manageable.

That illusion collapsed in January 2026. The company revealed its net asset value was closer to seven dollars. Shares sank again. Confidence vanished.

Now, investors say those earlier valuations were inflated all along. And more shareholders are joining the lawsuit.

Ultragenyx Pharmaceutical Inc. promised a breakthrough. A rare disease drug. Strong data. And real hope for patients with brittle bone disease. Executives said their drug, setrusumab, was boosting bone density and would cut fractures. They sounded confident. Repeatedly.

In August 2023, Ultragenyx said Phase III trials were on track. Through 2024, they doubled down. Bone gains would translate into fewer fractures. The studies were well designed. The risk was controlled.

Then July 9, 2025 hit. Ultragenyx admitted the second interim analysis failed. The stock dropped about 25% in a day. Still, investors were told to stay calm.

But on December 29, the truth landed. Both Phase III studies failed their main goals. No meaningful fracture reduction. The stock collapsed about 42% in one trading day.

Now, shocked investors say they were misled. And more shareholders are joining the lawsuit.

They promised hope. A breakthrough drug. And a future where fragile bones could finally get stronger.

Mereo BioPharma told investors its Phase 3 trials for setrusumab were on track. Executives said stronger bones would mean fewer fractures. They sounded confident. Repeatedly. Back in June 2023, Mereo hyped early trial data showing big gains in bone density. By 2024, they doubled down. Full enrollment. Strong signals. Confidence heading into final readouts.

But behind the scenes, it’s alleged that the key studies were failing. The drug was not reducing fractures, the main goal investors were sold on. On July 9, 2025, Mereo admitted one major trial missed its interim target. The stock collapsed about 42% in a single day. Still, executives reassured investors.

Then came December 29, 2025. The truth finally landed. Both Phase Three trials failed their primary endpoints. The stock crashed nearly 90%.

Now, shocked investors are fighting back. More shareholders are joining the lawsuit.

Here’s the story investors are now telling about Oracle Corporation. Oracle sold a powerful vision. AI everywhere. Data centers printing growth. Executives said massive spending would turn into revenue almost immediately.

But here’s what investors say was really happening. In June 2025, Oracle ramped up spending, promising cloud growth over 70%. By September, credit agencies warned Oracle was betting too much on one customer: OpenAI. The stock slid.

Then came December. Oracle reported weaker revenue, negative free cash flow over $10 billion, and a stunning jump in spending plans to about $50 billion. Days later, investors learned about nearly $250 billion in long term data center lease commitments. The stock dropped again. And again.

By mid December, a key funding partner walked away. Confidence collapsed. Shares sank more than 40% from earlier highs.

Now, investors say they were misled. And more shareholders are joining the lawsuit

Plug Power Inc. sold investors a bold dream. A nationwide network of clean hydrogen plants. Backed by a massive $1.66 billion government loan guarantee. The future looked green. Profitable. Secure.

But here’s what investors now say they were not told. In January 2025, Plug Power announced it had closed that huge Department of Energy loan to build up to 6 hydrogen plants. Executives said construction in Texas was coming soon. Through spring and summer, leadership kept reassuring Wall Street that funding was secure and the projects were moving forward.

Behind the scenes, the lawsuit claims the money was never guaranteed. The plants were far from certain. And Plug Power was likely to pivot away.

The cracks showed in October when top executives abruptly stepped down. In November, the company admitted it had suspended work tied to the loan. Days later, reports confirmed the hydrogen buildout was at risk. The stock sank hard. Confidence collapsed.

Now, investors say they were misled. And more shareholders are joining the lawsuit.

Picard Medical told investors it was saving lives. A breakthrough artificial heart. A fresh Nasdaq debut. Big optimism. But the stock story told a very different tale.

In early September 2025, Picard went public at $4 dollars a share, with only about 5% of its stock available to trade. That tiny float sent shares soaring fast. By October 23, the stock had spiked to nearly $14, with no real news to explain it.

Behind the scenes, reports later pointed to aggressive online stock promotion. Fake advisors. Social media hype. Coordinated buying pressure.

Then the illusion shattered. On October 24, Picard’s stock collapsed about 70% in a single day, crashing back below $4. Investors were blindsided. Confidence vanished. Millions in paper value wiped out.

Now, shareholders say they were never warned about the risks baked into this IPO. And more investors are stepping forward and joining the lawsuit.

Richtech Robotics told investors it had finally made it. A cutting-edge AI robot. A collaboration with Microsoft. Real validation. The stock took off.

On January 27, Richtech announced what it called a joint engineering effort with Microsoft’s AI labs. Executives said they were working side by side to power next-generation robots. Shares surged more than 40% in a single day. But the next morning, Richtech announced a $38.7 million private placement.

Then, the truth hit. On January 29, Hunterbrook Media reported that Microsoftsaid Richtech was just a customer in a short, standard program. No commercial deal. No collaboration. The stock collapsed. About 30% wiped out in two trading days.

Now investors say they were misled, the hype was manufactured, and the damage was real. More shareholders are now joining the lawsuit.

Ramaco told investors it was striking gold. A bold pivot into rare earth minerals. A brand-new mine. America’s first in decades.

In July 2025, Ramaco cut the ribbon on its Brook Mine in Wyoming. Executives said mining had already begun. Tons were coming out of the ground. The future looked huge.

But according to a lawsuit, that story wasn’t real.

From July through September, Ramaco kept telling investors the mine was active. In mid-September, the CEO even claimed multiple drilling rigs were operating on site.

Then, on October 23, a short seller dropped drone footage. No mining. No equipment. No activity. Just a staged opening and an empty pit.

The stock fell about 10% in a single day. Confidence collapsed. Now, investors say they were misled about the mine’s progress and are taking action. More shareholders are joining the lawsuit.

Beyond Meat told investors the hard part was over. Costs were coming down. Margins were improving.

And management promised a clear path to EBITDA-positive operations by the end of 2026. But behind that confidence, something big was quietly going wrong.

Starting in February 2025, executives kept stressing efficiency and discipline. They talked about cutting expenses and optimizing operations. What they did not talk about was the growing gap between the value of their factories, leases, and equipment and what those assets were actually worth.

On October 24, 2025, the truth started to slip out. Beyond Meat admitted it expected a material impairment tied to long lived assets. The stock dropped about 23%. Days later, the company delayed earnings. Shares slid again.

Then in November, investors finally saw the full damage. A $77 million write down. More losses. More disappointment. The stock kept falling. Now, stunned shareholders are fighting back. More investors are joining the lawsuit.

BellRing Brands told investors it was finally hitting its stride. Organic growth. Strong demand. A powerful protein tailwind.

But that story hid a very different reality.

From November 2024 through summer 2025, BellRing Brands said sales were surging because shoppers couldn’t get enough Premier Protein. Executives downplayed competition and talked up a so-called competitive moat.

What investors didn’t know is that much of that growth came from retailers stockpiling inventory. Not real consumer demand. Just shelves getting stuffed.

In May 2025, the truth started to crack. Retailers cut back orders. BellRing slashed guidance. The stock dropped about 19% in a day.

Then in August, the company finally admitted competition was biting. Hard.

Shares collapsed nearly 33% overnight.

Investors were stunned. Confidence evaporated.

Now, more shareholders are joining the lawsuit.

Vistagen told investors it was on the brink of a breakthrough. A first of its kind treatment for social anxiety. Phase Three success. FDA approval in sight.

From April 2024 through most of 2025, executives repeatedly praised their PALISADE-Three trial. They said enrollment was strong. Execution was tighter than ever. And results were expected to confirm earlier success. But behind the optimism, the story was very different. On December 17, 2025, the truth came out.

The Phase Three trial failed. No meaningful difference versus placebo. The core endpoint missed. Investors were stunned. Vistagen stock collapsed from about $4 to under $1 in a single day.

More than 80% gone. Confidence wiped out. Now, investors say they were misled. And more shareholders are joining the lawsuit.

Bath and Body Works told investors it had cracked the code for growth. New categories. New customers. A fresh chapter beyond soaps and candles. Men’s products. Hair. Lips. Laundry. Management said these “adjacencies” would fuel the future. But behind the scenes, that story was falling apart.

From June 2024 through 2025, executives kept pitching these new lines as a growth engine. In August 2025, reality hit. Earnings missed. Profits dropped more than 50%. Guidance was cut. The stock slid.

Then came November. Bath and Body Works admitted those adjacencies were not growing the customer base at all. They had distracted from the core business. Promotions were masking weak demand.

Investors were blindsided. Shares collapsed about 25% in a single day. Now, shareholders say they were misled about what was really driving growth. And more investors are stepping forward to join the lawsuit.

CoreWeave sold investors a dream. The AI hyperscaler. Massive demand. Billions in long-term contracts.

In March 2025, just weeks before its IPO, CoreWeave hyped a deal worth nearly $12 billion tied to AI growth. The stock took off. By June, shares had surged more than 300%.

Executives kept saying demand was “robust” and “unprecedented.” But behind the scenes, there was a problem. CoreWeave could not build data centers fast enough. Its entire business depended on a single third-party provider to deliver powered shells. And those builds were already falling behind. In October, a key acquisition collapsed. In November, CoreWeave finally cut revenue guidance, blaming delays. Days later, executives admitted the delays hit more than one site.

Then in December, reports revealed those problems had been flagged months earlier. The stock slid from triple digits to under $70. Now, investors say they were kept in the dark. And more shareholders are joining the lawsuit.

Ardent Health sold investors a clean story. Strong collections. Disciplined accounting. A smooth IPO. But behind the optimism, something was off.

When Ardent went public in July 2024, executives said they carefully reviewed what patients and insurers would actually pay. They claimed uncollectible bills were written off on time. That was the promise.

According to the lawsuit, the reality was very different. Ardent allegedly relied on a rigid 180 day cutoff that delayed write offs and made receivables look stronger than they were. At the same time, payor denials were piling up, even as executives brushed them off as slow payments. Then came November 12, 2025. Ardent revealed a $43 million dollar revenue hit, slashed its guidance, and boosted liability reserves.

The stock dropped about 34% overnight. Now, shocked investors are fighting back. More shareholders are joining the lawsuit.

Varonis told investors the future was bright. A smooth transition to SaaS. Stronger renewals. Growing recurring revenue. Executives said customers loved the move. They said conversions were strong. They even raised guidance again and again.

From February 2025 through the summer, Varonis promised annual recurring revenue growth in the mid-teens. They claimed on-prem customers were lining up to switch. Especially federal customers. But behind the scenes, that story was cracking. Conversions were stalling. Renewals were weaker than expected. And many customers just were not buying into the SaaS push.

Then, in October 2025, the truth finally came out. Varonis missed its revenue targets. Slashed guidance. Announced layoffs. And admitted its on-prem business was falling apart. The stock collapsed about 48% in a single day. Investors were stunned. Confidence vanished. Now, more shareholders are joining the lawsuit.

Fermi sold investors a bold future. Massive nuclear power. AI data centers. And a flagship project called Project Matador that was supposed to change everything.

In October 2025, Fermi went public at $21 a share, raising about $745 million. Executives said demand was strong and a major tenant was lined up to help fund construction.

By November, Fermi told investors that tenant had committed $150 million to help build the project. It sounded locked in. But behind the scenes, the entire project depended on that single tenant’s money.

Then, in December 2025, the truth hit. That tenant walked away. The funding vanished. The stock dropped about 30% in one day and later sank nearly 60% from the IPO price. Now, stunned investors say they were misled. And more shareholders are joining the lawsuit.

Agilon Health sold investors a confident story. Strong guidance. Strategic actions. A stronger foundation for growth. But that optimism did not last long.

In February 2025, agilon told the market it was on track for a solid year. Executives promised improved margins, controlled costs, and hundreds of thousands of Medicare Advantage members coming onto the platform.Then in May, management doubled down. They said the company was still on track to hit its full-year guidance.

Behind the scenes, the lawsuit says industry headwinds were worsening and those so-called strategic fixes were not going to help until 2026.

The truth came out in August. The CEO stepped down. The company suspended its 2025 guidance. Losses mounted. Revenue fell. Medical margins turned negative.

Investors were stunned. The stock collapsed by about 50% in a single day.

Now, shareholders say they were misled. And more investors are joining the lawsuit.

Klarna sold investors a feel-good story. Smart tech. Smarter credit. Responsible growth. But the truth hit hard.

In March 2025, Klarna filed for its long-awaited IPO, promising cutting-edge underwriting and disciplined risk controls. By September, shares priced at $40, and executives said their models could safely handle consumer lending at scale.

What investors didn’t hear was who Klarna was really lending to. The lawsuit says many borrowers were already under financial stress. Even taking out loans for fast food. Risky loans that should have raised red flags.

Then in November, the cracks showed. Klarna reported a $95 million loss and sharply higher credit loss provisions. The stock slid to about $31 dollars. Confidence vanished. Now investors say they were misled. And more shareholders are stepping forward to join the lawsuit.

SLM Corporation thought it had a steady story. High quality student loans. Strong credit. Delinquencies under control. That was the pitch. But behind the scenes, the cracks were already showing.

In late July 2025, Sallie Mae told investors rising delinquencies were just seasonal. Executives said their loan modification programs were working. Everything was “normal.” Then the data told a different story.

By mid-August, an analyst report revealed early stage delinquencies were surging far beyond seasonal levels. Not a small bump. A serious spike. The market reacted fast.

SLM shares fell about 8% in a single day as investors realized the risks had been downplayed. The loans weren’t as stable as promised. And the mitigation programs weren’t fixing the problem.

Confidence disappeared. Investors were blindsided. Now, shareholders say they were misled about the true health of Sallie Mae’s loan book. And more investors are joining the lawsuit.

Coupang sold investors a story about trust, growth, and world class technology. A fast growing ecommerce giant. Strong systems. Customer data safe.

But behind the scenes, something was already very wrong.

According to a new securities lawsuit, a former employee quietly kept access to Coupang’s internal systems. For months. Undetected. From August 2025 through November, executives kept filing reports saying cyber risks were under control.

Then on November 18, Coupang finally discovered the breach. More than 33 million customer records exposed. Names. Emails. Delivery addresses. Nearly its entire user base.

Investors were not told right away.

The truth started leaking out at the end of November through media reports. Regulators stepped in. Police raided offices. And the CEO of Coupang’s Korean unit resigned.

The stock slid again and again. Confidence collapsed. Now, investors say they were kept in the dark. And more shareholders are joining the lawsuit.

F5 told investors it was the gold standard in cybersecurity. Best in class. Unmatched protection. The company everyone trusted to keep data safe.

But behind the scenes, something was very wrong.

From October 2024 through October 2025, F5 executives repeatedly bragged about their security strength, especially around their flagship BIG IP platform. They said it was driving growth, renewals, and confidence.

What they did not say was that F5 was already dealing with a long term, persistent security breach. Hackers had compromised internal systems, including sensitive BIG IP source code.

On October 15, the company finally admitted the breach. The stock dropped about 14% in two days. Then, on October 27, the rest of the truth came out. Sales slowed. Renewals suffered. Costs surged. The stock fell another 11%.

Investors were blindsided.

Now, shareholders say they were misled. And more investors are joining the lawsuit.

Integer Holdings told investors it was riding a powerful growth wave.
 Electrophysiology devices. Pulse field ablation. Strong demand. Clear visibility.
 Executives said the future looked brighter every quarter.

But behind that confidence, something was breaking.

Starting in July 2024, Integer repeatedly claimed its heart device business was growing faster than the market. Management said demand was strong and accelerating through 2025. They told investors their electrophysiology products were a major growth driver.

The lawsuit says that was not true. Demand for two key EP devices was already sliding. Growth was slowing. And the company did not tell investors.

Then, on October 23, 2025, the truth came out. Integer cut guidance. Executives admitted adoption of those EP products was slower than expected and would keep dragging into 2026.

The stock collapsed about 32% in a single day.

Investor confidence vanished.

Now, more investors are joining the lawsuit.

Blue Owl promised steady growth. Safe income. A rock-solid private credit machine.
But behind all that confidence… something was cracking.

Here’s what really happened.

In early 2025, executives kept telling investors there was no meaningful pressure from redemptions. They repeated it in February, May, and August. But OBDC II — one of their major funds — was getting hit with rising withdrawals all year.

By late October, earnings missed expectations. On November 5, Blue Owl revealed a surprise plan to merge OBDC II into the publicly traded OBDC… and quietly said OBDC II would halt redemptions.

Then on November 16, the truth spilled out. Reports showed OBDC II investors could face a 20% hit and wouldn’t be allowed to cash out until the merger closed in 2026. The stock slipped again. Confidence evaporated.

Now, more investors are joining the lawsuit.

Bitdeer promised a future powered by its next-generation SEALMINER chips. Lightning-fast. Ultra-efficient. Ready for mass production. Investors were excited. It sounded like a breakthrough.

But the truth was very different.

Starting in June 2024, executives kept saying the A4 rigs and their SEAL04 chip were “on track” for release in 2025. They repeated it in August, November, February, even through the summer of 2025. They claimed a five-joule-per-terahash chip was coming, and that mass production was right around the corner.

Behind the scenes, the project was falling apart. Engineering setbacks. A sudden dual-design scramble. Delays they never revealed. And by September, early samples weren’t anywhere near the performance Bitdeer had promised.

Then came November 10, 2025. Bitdeer reported a massive $266 million loss. Worse, they admitted the next-generation SEAL04 chip was “significantly delayed.” Investors were stunned. The stock dropped about 14% overnight.

Now, more shareholders are joining the lawsuit.

DeFi Technologies sold investors a story of “low‑risk” crypto arbitrage powering explosive, reliable growth. DeFi Alpha, its proprietary trading desk, was billed as the engine: sophisticated, disciplined, and generating big gains with no losses.​

But the market was shifting. Other digital‑asset treasury firms crowded into the same trades, price gaps tightened, and DeFi Alpha’s execution slowed—even as management kept talking about “pivotal” returns and “firing on all cylinders.”​

On November 6, 2025, DeFi quietly admitted that rivals had absorbed or delayed a significant share of arbitrage opportunities over the past year, and the stock slipped about 7.5%.​

Then November 14 hit. DeFi reported nearly a 20% revenue drop, slashed its 2025 forecast from roughly $218.6 million to $116.6 million, and announced the CEO was stepping down.​

The stock plunged around 27%. Now investors are suing.